Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509873 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 578
- Enrollment target
NCT00509873 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 578 participants.
The verdict
NCT00509873, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 578 participants
- Enrollment target
Study Summary
The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
Interventions
- DRUG placebo eye drops
- DRUG Gatifloxacin 0.5% eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 578 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509873
The ClinicalTrials.gov registry entry for NCT00509873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 578 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo eye drops is the first listed.
NCT00509873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00509873 about?
NCT00509873 is a clinical study titled "A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis". The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
What is the current status of trial NCT00509873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 578 participants. The study started on 2007-08. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00509873?
The interventions under investigation include: placebo eye drops (DRUG), Gatifloxacin 0.5% eye drops (DRUG).
Who is sponsoring clinical trial NCT00509873?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.